Concomitant chemoradiotherapy for treatment of non-small cell lung cancer - the Conrad study

Phase 3

Completed

• Conditions: on-small cell lung cancer; Cancer; Malignant neoplasm of bronchus and lung

• Registration Number: ISRCTN63778716
• Lead Sponsor: Pierre Fabre Pharma Norden AB (Sweden)

Brief Summary

1. 2013 results in https://www.ncbi.nlm.nih.gov/pubmed/23963145 (added 21/01/2019) 2. 2014 results in https://www.ncbi.nlm.nih.gov/pubmed/24807158 (added 21/01/2019) 3. 2015 results in https://www.ncbi.nlm.nih.gov/pubmed/25481662 (added 21/01/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-05-29
• Study Completion: 2013-11-15
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 352

Inclusion Criteria

1. Chemo-naive patients with non-small cell lung cancer (NSCLC) locally advanced stage III, not candidates for radical radiotherapy and with no pleural effusion
2. Performance status (World Health Organization [WHO]) 0 - 2
3. Ability to understand oral and written study information
4. Both males and females, no age limit
5. S-creatinine less than 1.5 times upper reference limit, bilirubin and S-transaminase levels less than 2 times upper limits. Normal white blood-cell and platelet count.

Exclusion Criteria

1. Other active malignancies
2. Pregnancy or breast feeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified